The effect of a next generation factor VIII mimetic bispecific antibody (Mim8) on assays of factor VIII activity and thrombin generation

Mim8 is a next generation bispecific antibody developed for the prophylactic treatment of hemophilia A. The sensitivity of activated plasma thromboplastin time (APTT), assays measuring factor VIII activity (FVIII:C) and thrombin generation to plasma containing Mim8 was assessed. Congenital severe he...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of thrombosis and haemostasis Vol. 21; no. 3; pp. 480 - 487
Main Authors:	Bowyer, Annette Elizabeth, Kitchen, Steve, Ezban, Mirella
Format:	Journal Article
Language:	English
Published:	England Elsevier Inc 01.03.2023
Subjects:	Animals Antibodies, Bispecific - therapeutic use bispecific antibody Cattle chromogenic Factor VIII - metabolism FVIII hemophilia Hemophilia A - drug therapy Hemostatics - therapeutic use Humans Indicators and Reagents one-stage Partial Thromboplastin Time Thrombin - metabolism Thromboplastin - therapeutic use one-stage bispecific antibody hemophilia chromogenic FVIII
ISSN:	1538-7836, 1538-7836
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!